Axovant Gene Therapies Ltd.
(NASDAQ : AXGT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.36%198.321.3%$525.50m
GILDGilead Sciences, Inc.
1.37%66.870.9%$355.36m
ALXNAlexion Pharmaceuticals, Inc.
0.98%106.712.0%$331.00m
ILMNIllumina, Inc.
0.68%307.273.5%$318.06m
BIIBBiogen Inc.
2.52%241.551.3%$313.76m
CELGCelgene Corporation
0.57%99.521.3%$296.26m
VRTXVertex Pharmaceuticals Incorporated
1.51%178.801.9%$177.39m
AAgilent Technologies, Inc.
0.78%78.681.6%$177.23m
REGNRegeneron Pharmaceuticals, Inc.
3.16%295.212.6%$171.65m
SRPTSarepta Therapeutics, Inc.
-2.28%83.4214.6%$141.94m
EXASExact Sciences Corporation
-0.05%103.3524.1%$138.68m
ACADACADIA Pharmaceuticals Inc.
-2.12%40.8013.9%$122.79m
INCYIncyte Corporation
2.30%79.922.5%$87.16m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.6510.2%$76.37m
BMRNBioMarin Pharmaceutical Inc.
0.15%76.114.3%$75.73m

Company Profile

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.